Cargando…
Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy
Several histone deacetylase inhibitors including Vorinostat have received FDA approval for the treatment of haematological malignancies. However, data from these trials indicate that Vorinostat has limited efficacy as a monotherapy, prompting the need for rational design of combination therapies. A...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620222/ https://www.ncbi.nlm.nih.gov/pubmed/28978082 http://dx.doi.org/10.18632/oncotarget.18910 |